Stephen Simpson, CFA
Long only, growth at reasonable price, value, research analyst

Biogen Idec Has BG-12, But What Excites Investors Next?

If Biogen Idec (NASDAQ:BIIB) follows the usual pattern, the launch of BG-12 for multiple sclerosis isn't likely to generate huge investor enthusiasm (another example of "buy the rumor, sell the news"). That's particularly true given management's effort to take down the high end of BG-12 launch expectations within the last month. Accordingly, while Biogen Idec is a well-run franchise with a great niche in MS, and may well attract attention from a larger pharma, the company may need another exciting asset in its pipeline to keep up investor enthusiasm.

Good Execution In The Fourth Quarter...

Biogen Idec did well in terms of the reported numbers for the fourth quarter. Revenue rose 7% from last year and came in...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details